Dr. Ali Ghoochani, Postdoctoral Fellow in Stoyanova Lab awarded Department of Defense, Prostate Cancer Research Program, Early Investigator Award for his project title:
“Ferroptosis Induction is a Novel Therapeutic Strategy for Advanced Prostate Cancer”
The overall goal of the proposed research is to develop novel therapeutic strategies that improve outcomes for men with lethal prostate cancer. In the proposed research, we aim to assess the therapeutic potential of ferroptosis induction (Iron-dependent cell death) by erastin treatment in advanced prostate cancer. We will also evaluate the therapeutic potential of ferroptosis induction in combination with FDA approved second-generation anti-androgens Enzalutamide and Abiraterone. Additionally, we will investigate the molecular mechanisms through which ferroptosis induction affects prostate cancer. Completion of the proposed research will lead to the development of novel therapeutic strategies for advanced prostate cancer and thus significantly reduce mortalities associated with lethal prostate cancer.
